It in primarily caused when infection from other parts of the body spreads through the bloodstream to the heart chambers and valves. It primarily affects the damaged or weakened parts of the heart and not the healthy one.
Endocarditis Therapeutics Market: Introduction
- Endocarditis is an infection that occurs at the inner lining of heart chambers and heart valves
- It in primarily caused when infection from other parts of the body spreads through the bloodstream to the heart chambers and valves. It primarily affects the damaged or weakened parts of the heart and not the healthy one.
Read Report Overview - https://www.transparencymarketresearch.com/endocarditis-therapeutics-market.html
- Endocarditis if not treated at an early stage could damage the entire heart and heart valves and lead to life-threatening complications. People with damaged or weakened heart valves, artificial heart valves, and other heart diseases are more susceptible to endocarditis.
- Common symptoms of endocarditis are fever and chills, a changed heart murmur, fatigue, aching joints and muscles, night sweating, and pain in the chest during breathing
- Endocarditis is caused due to the spread of infection from other parts of the body. Hence, the treatment is aimed at the underlying causes of endocarditis such as use of antibiotics.
Global Endocarditis Therapeutics Market: Key Drivers
- The global endocarditis therapeutics market is primarily driven by high prevalence and increase in incidence rates of endocarditis across the globe. According to Oxford Medicine, the worldwide prevalence of endocarditis is around 3 to 8 people per 100,000 population. The incidence rate of endocarditis is expected to rapidly increase in some parts of the world.
- High prevalence of cardiovascular disorders, significantly large number of people undergoing valve replacement surgeries, and cardiac stroke across the globe are likely to drive the global endocarditis therapeutics market during the forecast period
- Underlying causes of endocarditis such HIV infection, diabetes mellitus, implantation of intracardiac electronic devices, and degenerative valvular heart disease are projected to boost the growth of the global endocarditis therapeutics market
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=74058
Glycopeptide Antibiotics Segment to Dominate Global Market
- In terms of drug class, the global endocarditis market can be classified into glycopeptide antibiotics, cephalosporin, carbapenems, aminoglycosides, miscellaneous antibiotics, and others. The glycopeptide antibiotics segment is anticipated to dominate the global endocarditis therapeutics market during the forecast period.
- Glycopeptide antibiotics, especially Vancomicin, are the most commonly used antibiotics in the treatment of endocarditis. Glycopeptide antibiotics inhibit bacterial cell wall formation by preventing peptidoglycan synthesis.
Intravenous to be Highly Attractive Segment
- Based on route of administration, the global endocarditis therapeutics market can be divided into oral and intravenous. Intravenous is expected to be the leading segment of the global market during the forecast period.
- Intravenous is the most commonly preferred route of administration for the treatment of endocarditis by health care professionals across the globe
Request for Analysis of COVID-19 Impact on Endocarditis Therapeutics Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=74058
Asia Pacific Endocarditis Therapeutics Market to Grow at Rapid Pace
- In terms of region, the global endocarditis therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global market during the forecast period. However, the region is anticipated to lose market share by the end of 2027.
- High prevalence of cardiovascular disorders, significantly increasing number of heart valve replacement surgeries and other cardiovascular disorders in the region, well-established health care infrastructure, and high awareness about various cardiovascular disorders are likely to contribute to North America’s high share of the global market. Moreover, early adoption of technologically advanced diagnostic tools and techniques for endocarditis and large base of pharmaceutical and biotechnology companies are projected to fuel the growth of the endocarditis therapeutics market in the region during the forecast period.
- The endocarditis therapeutics market in Asia Pacific is anticipated to expand at a high CAGR during the forecast period, owing to rapidly increasing cardiovascular surgical procedures in densely populated countries such as India, China, and Hong Kong and improving health care infrastructure.
- Moreover, high prevalence of bacterial, fungal, and viral infections in the region is a key factor expected to drive the endocarditis therapeutics market in Asia Pacific during the forecast period
Pre Book Endocarditis Therapeutics Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=74058<ype=S
Key Players Operating in Global Market
The global endocarditis therapeutics market is highly fragmented, with a large number of global players accounting for majority of the market share. Key players operating in the global endocarditis therapeutics market are:
- Pfizer, Inc.
- Novartis AG
- Elli Lilly and Company
- Merck & Co., Inc.
- Allergan
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Limited
- Mylan N.V.
- Fresenius Kabi AG
Browse More Trending Reports by Transparency Market Research:
Point-of-care Diagnostics Market: The point-of-care diagnostics market stood at US$6.8bn in 2016 and is expected to reach US$ 11.7bn by the end of 2024 with a stellar CAGR of 6.9 percent across the forecast period according to the report by Transparency Market Research (TMR).
Contact Lens Market: The global contact lens market is projected to witness considerable rise owing to rising prevalence of increased preference for contact lenses over prescribed eyeglasses for aesthetics purposes and rising cases of vision related problems like myopia.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/